Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 205

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 205
---
. Various PPA and Impairment studies of Given Imaging SBUs (A global, leader in              
 patient-friendly solutions for visualizing, detecting, and monitoring GI disorders).                |
| ■ | Kanit                                                                                               
 Hashalom. Numerous valuations of subsidiaries such as Tambour, Sonol, Supergas and GES.             |

Yours faithfully,

Moore Financial Consulting Ltd.

| Moore Financial Consulting |

| MIRA Pharmaceuticals, Inc. | April 2025   |
| Valuation                  | Page 4 of 28 |

<div align='center'>Table of Contents</div>

| The             
 Company         |  5 |
| The             
 Markets         |  8 |
| Methodology     | 16 |
| Valuation       | 19 |
| Appendix        
 – Discount Rate | 27 |
| Appendix        
 – Peer group    | 28 |

| Moore Financial Consulting |

| MIRA Pharmaceuticals, Inc. | April 2025   |
| Valuation                  | Page 5 of 28 |

The Company

MIRA Pharmaceuticals, Inc. (“MIRA,” or the “Company”), is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The Company holds exclusive license rights in the U.S., Canada and Mexico for Ketamir-2, a novel, patent pending oral ketamine analog under pre-clinical investigation to potentially deliver ultra-rapid antidepressant effects, providing hope for individuals battling neuropathic pain.

Additionally, the Company’s novel oral pharmaceutical Cannabinoid, MIRA-55, is currently under investigation for its potential to help people suffering from Mild Cognitive Impairment (MCI), as well as anxiety and cognitive decline, symptoms often associated with early-stage dementia. MIRA-55, if approved by the U.S. Food and Drug Administration (“FDA”), could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders.

The U.S. Drug Enforcement Administration’s (“DEA”) scientific reviews of both Ketamir-2 and MIRA-55 concluded that they would not be considered a controlled substance or listed chemical under the Controlled Substances Act (“CSA”) and its governing regulations.

On March 2025, the Company announced the approval and upcoming initiation of its Phase 1 clinical trial for Ketamir-2, the Company’s novel oral ketamine analog in development for Diabetic Neuropathic Pain (DNP), with subject recruitment scheduled